Supplementary Material Submitted to *CNS Drugs*

CHANGES IN CATAPLEXY FREQUENCY IN A CLINICAL TRIAL OF LOWER-SODIUM OXYBATE WITH TAPER AND DISCONTINUATION OF OTHER ANTICATAPLECTIC MEDICATIONS

Yves Dauvilliers[a,b]; Karel Šonka[c]; Richard K. Bogan[d]; Markku Partinen[e,f]; Rafael Del Rio Villegas[g]; Nancy Foldvary-Schaefer[h]; Roman Skowronski[i]; Abby Chen[i]; Jed Black[i,j]; Franck Skobieranda[k]; Michael J. Thorpy[l]

[a]Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France; [b]University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France; [c]Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; [d]University of South Carolina School of Medicine, Columbia, SC, USA; [e]Helsinki Sleep Clinic, Terveystalo Healthcare, Helsinki, Finland; [f]Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland; [g]Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, Madrid, Spain; [h]Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, USA; [i]Jazz Pharmaceuticals, Palo Alto, CA, USA; [j]Stanford University Center for Sleep Science and Medicine, Redwood City, CA, USA; [k]Jazz Pharmaceuticals, Philadelphia, PA, USA; [l]Albert Einstein College of Medicine, Bronx, NY, USA

Corresponding Author:
Yves Dauvilliers, MD, PhD
ORCID: 0000-0003-0683-6506
Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital
80 Avenue Augustin Fliche
34295, Montpellier, France
E-mail: y-dauvilliers@chu-montpellier.fr
Phone: 3314067337277

Yves Dauvilliers[a,b]; Karel Šonka[c]; Richard K. Bogan[d]; Markku Partinen[e,f]; Rafael Del Rio Villegas[g]; Nancy Foldvary-Schaefer[h]; Roman Skowronski[i]; Abby Chen[i]; Jed Black[i,j]; Franck Skobieranda[k]; Michael J. Thorpy[l]

[a]Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France; [b]University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France; [c]Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; [d]University of South Carolina School of Medicine, Columbia, SC, USA; [e]Helsinki Sleep Clinic, Terveystalo Healthcare, Helsinki, Finland; [f]Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland; [g]Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, Madrid, Spain; [h]Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, USA; [i]Jazz Pharmaceuticals, Palo Alto, CA, USA; [j]Stanford University Center for Sleep Science and Medicine, Redwood City, CA, USA; [k]Jazz Pharmaceuticals, Philadelphia, PA, USA; [l]Albert Einstein College of Medicine, Bronx, NY, USA

Corresponding Author:
Yves Dauvilliers, MD, PhD
E-mail: y-dauvilliers@chu-montpellier.fr

Online Resource 1. Participant Disposition: Discontinuations During OLOTTP and Prior to Taking Randomized Drug in DBRWP, by Treatment at Study Entry (Safety Population)

	Group A	Group B	Group C	Group D	
Parameter, n (%)	**SXB Only (n=52)**	**SXB + Other Anticataplectics (n=23)**	**Other Anticataplectics (n=36)**	**Anticataplectic Naive (n=90)**	**Total (N=201)**
Safety population[a]	52 (100.0)	23 (100.0)	36 (100.0)	90 (100.0)	201 (100.0)
Completed OLOTTP	45 (86.5)	14 (60.9)	26 (72.2)	70 (77.8)	155 (77.1)
Discontinued early from OLOTTP	7 (13.5)	9 (39.1)	10 (27.8)	20 (22.2)	46 (22.9)
TEAE[b]	2 (3.8)	5 (21.7)	5 (13.9)	6 (6.7)	18 (9.0)
Protocol deviation	0 (0.0)	0 (0.0)	2 (5.6)	6 (6.7)	8 (4.0)
Withdrawal by participant	2 (3.8)	1 (4.3)	0 (0.0)	3 (3.3)	6 (3.0)
Noncompliance	2 (3.8)	0 (0.0)	0 (0.0)	2 (2.2)	4 (2.0)
Investigator decision	0 (0.0)	1 (4.3)	2 (5.6)	0 (0.0)	3 (1.5)
Lost to follow-up	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.3)	3 (1.5)
Sponsor decision	1 (1.9)	1 (4.3)	0 (0.0)	0 (0.0)	2 (1.0)
Lack of efficacy	0 (0.0)	0 (0.0)	1 (2.8)	0 (0.0)	1 (0.5)
Other[c]	0 (0.0)	1 (4.3)	0 (0.0)	0 (0.0)	1 (0.5)
Discontinued prior to taking randomized drug in DBRWP	4 (7.7)	0 (0.0)	5 (13.9)	12 (13.3)	21 (10.4)
Completed OLOTTP but did not enter SDP	0 (0.0)	0 (0.0)	3 (8.3)	3 (3.3)	6 (3.0)
Entered SDP but discontinued early from SDP[d]	1 (1.9)	0 (0.0)	1 (2.8)	3 (3.3)	5 (2.5)
Completed SDP but did not enter DBRWP	2 (3.8)	0 (0.0)	1 (2.8)	5 (5.6)	8 (4.0)
Entered DBRWP but were randomized in error and did not take study drug	1 (1.9)	0 (0.0)	0 (0.0)	1 (1.1)	2 (1.0)
Efficacy population[e]	41 (78.8)	14 (60.9)	21 (58.3)	58 (64.4)	134 (66.7)

Percentages within each group were calculated using the starting number of participants as the denominator.
DBRWP, double-blind randomized withdrawal period; OLOTTP; open-label, optimized treatment and titration period; SDP, stable-dose period; SXB, sodium oxybate; TEAE, treatment-emergent adverse event.
[a]All participants who took at least 1 dose of study medication.
[b]Including 7 who discontinued due to worsening cataplexy, including 4 participants in group B (SXB+other anticataplectics) and 3 participants in group C (other anticataplectics).
[c]Without additional information.
[d]For reasons including protocol deviation (n=3), TEAE (n=1), and lost to follow-up (n=1).
[e]All randomized participants who took at least 1 dose of double-blind study medication and completed at least 1 set of post-randomization efficacy assessments.